Dr. Weinstein was a lead clinical writer and reviewer for the preparation of clinical sections of the Biologics License Application (BLA) submitted to the Food and Drug Administration (FDA) to support the registration of rilonacept, Regeneron’s novel product candidate for the treatment of cryopyrin-associated periodic syndromes (CAPS), a group of rare, inherited, inflammatory conditions.
In his previous position as the Senior Director of Endocrinology, Dr. Weinstein designed, implemented and analyzed clinical trial programs to support the development of endocrine product candidates. Among many of his achievements at Regeneron, he led the design and implementation of a large phase III clinical study program in obesity, and successfully completed pivotal studies in CAPS.
Dr. Weinstein, who began working for Regeneron in 2001, has over a decade of experience in the healthcare industry, including positions in medical affairs and clinical development at Knoll Pharmaceutical Company, as well as in academia as an Assistant Professor of Medicine at The Mount Sinai School of Medicine in New York City. Dr. Weinstein is the author of many published, peer-reviewed basic and clinical research reports.
Dr. Weinstein received a Master of Science in Physiology at Cornell University as well as a Master of Science in Physiology and Biophysics at the Albert Einstein College of Medicine, Yeshiva University, where he later went on to receive an M.D. and Ph.D.
About Regeneron Pharmaceuticals, Inc. Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's worldwide web site at www.regeneron.com.
Forward Looking Statement This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of our drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize our drug candidates, competing drugs that are superior to our product candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement, including our agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or to terminate without any product success, risks associated with third party intellectual property, and other material risks. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-Q for the quarter ended September 30, 2007. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.
Contact Information:
Laura Lindsay Corporate Communications 914.345.7800 laura.lindsay@regeneron.com
Lauren Tortorete Media Relations 212.845.5609 ltortorete@biosector2.com
